Quick Answer
Phathom Pharmaceuticals, Inc. reported R&D Expense of $32.78 million for fiscal year 2025.
Phathom Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $32.78M | -3.8% |
| 2024 | $34.08M | -31.7% |
| 2023 | $49.90M | -30.2% |
| 2022 | $71.44M | -1.2% |
| 2021 | $72.34M | -26.3% |
| 2020 | $98.15M | +381.7% |
| 2019 | $20.37M | +101770.0% |
| 2018 | $20.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.03M | -19.2% | -22.6% |
| June 30, 2025 | $9.08M | +23.0% | -1.2% |
| March 31, 2025 | $9.18M | -2.6% | +5.6% |
| September 30, 2024 | $8.69M | -29.1% | +17.9% |
| June 30, 2024 | $7.38M | -42.2% | -21.8% |
| March 31, 2024 | $9.43M | -17.8% | -23.1% |
| September 30, 2023 | $12.26M | -35.5% | -3.9% |
| June 30, 2023 | $12.76M | -32.2% | +11.2% |
- Phathom Pharmaceuticals, Inc. showed a decrease of -3.8% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Phathom Pharmaceuticals, Inc.’s r&d expense has grown by 163800.0% (from $20.0 thousand to $32.78 million).
- The most recent figure is from Phathom Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: